{"schema_version":"1.0","type":"article","title":"Sales of a Star Heart Drug Have Halved. Can Novartis’s Next Medicines Take Over in Time?","url":"https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation-en.md","lang":"en","date":"2026-10-06","publish_at":"2026-10-06T20:00:00+08:00","updated_at":"2026-10-06","category":"商業分析系列","topic":"商業分析系列","tags":["Novartis","諾華","Entresto","Avidity","del-desiran","pelacarsen","remibrutinib","資本配置","新藥授權","專利到期"],"summary":"Novartis’s heart medicine Entresto recorded a 50% year-on-year sales decline in US dollars in the second quarter of 2026. In September, pelacarsen and del-desiran, previously listed for expected submissions over the next two years, both reported missed Phase 3 primary endpoints. Revenue erosion is already in the financial statements, while the filing assumptions for those two candidates need reassessment.","key_points":[],"facts":[],"sections":[],"references":[],"images":[{"alt":"The upper tier uses heart, breast-cancer-cell and nerve-fiber illustrations for Entresto, Kisqali and Kesimpta. Entresto is labeled with a 50% year-on-year US-dollar sales decline in Q2 2026. The lower tier is labeled “Candidates / new indications,” with fine dashed lines connecting clinical validation, regulatory review and market adoption.","url":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation-en/FIG01_EN_R2.png"},{"alt":"In the upper tier, a soluble antibody carrying siRNA approaches extracellular TfR1 on a muscle-cell membrane through a Fab end, with its Fc directed away from the membrane. Inside the cell, dashed arrows connect a separate siRNA schematic through a node labeled “Designed to reduce target RNA” to a continuous red strand labeled “Toxic DMPK mRNA”; the dashed lines denote the intended mechanism. A separate lower tier shows hand-function measurement and a study record for the 54-week HARBOR trial, labeled “Primary endpoint not met.”","url":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation-en/FIG02_EN_R2.png"},{"alt":"The upper lane uses liver-cell RNA, cardiovascular illustrations and a study record for pelacarsen, labeled “Primary endpoint not met.” The lower lane shows remibrutinib with a BTK node inside a B cell but outside its nucleus, an inhibitory bar ending at BTK, and a nerve fiber. Its result label reads “Annualized relapse-rate endpoint met.” The two lanes refer to separate studies.","url":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation-en/FIG03_EN_R2.png"},{"alt":"Three distinct areas show the Avidity acquisition, subsequent R&D and impairment assessment. The acquisition area states completion on February 27, 2026, approximately US$12 billion in cash consideration, and a platform with multiple programs. Research and valuation documents indicate separate decisions for further R&D and impairment. The lower area brings them into the next capital-allocation decision and distinguishes impairment from another acquisition payment.","url":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation-en/FIG04_EN_v1.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/novartis-growth-succession-capital-allocation-en/FIG01_EN_R2.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-06）。Sales of a Star Heart Drug Have Halved. Can Novartis’s Next Medicines Take Over in Time?。https://drugnews.com.tw/articles/2026-10-06-novartis-growth-succession-capital-allocation-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-10-06-novartis-growth-succession-capital-allocation.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}